Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: Clusterin (also known as apolipoprotein J) is a molecular chaperone that participates in a number of biological processes, such as inflammation and apoptosis. Recent data suggest its possible role in the development of chronic autoimmune diseases. The aim of this study was to analyse skeletal muscle expression and serum levels of clusterin in patients with idiopathic inflammatory myopathies (IIM) and in healthy individuals, and to investigate their potential association with clinical disease activity.
Methods: Protein expression of clusterin in muscle tissues was determined by immunohistochemistry in 5 patients with polymyositis (PM), 5 patients with dermatomyositis (DM) and in 5 control subjects. Clusterin mRNA expression in skeletal muscle samples was analysed in 10 patients with IIM and 10 healthy donors by qPCR. Clusterin serum levels were measured by commercial ELISA kit (BioVendor) in 65 IIM patients (28 PM, 27 DM, 10 immune-mediated necrotizing myopathy (IMNM)) and 65 age-/sex-matched healthy individuals. Patients with PM and DM fulfilled Bohan and Peter diagnostic criteria. IMNM was diagnosed according to ENMC 2003 criteria. Disease activity was assessed using myositis disease activity assessment visual analogue scales (MYOACT), myositis intention to treat index (MITAX), health assessment questionnaire (HAQ) and global disease assessment evaluated by patient and doctor. Data are presented as mean ± SD.
Results: Clusterin mRNA expression in muscle tissues was significantly increased in patients with IIM compared to healthy donors (p=0.029). Clusterin protein was found to be accumulated in the cytoplasm of regenerating muscle fibers in patients with PM/DM. Serum clusterin levels were significantly higher in all IIM patients than in healthy subjects (87.1 ± 22.8 vs 66.9 ± 11.9, p<0.0001) and also in individual subsets of patients in comparison to the control group (PM: 86.1 ± 23.2, DM: 87.7 ± 24.7, IMNM: 88.15 ± 18.0, p<0.0001 for all). Clusterin levels in all patients with IIM positively correlated with MYOACT (r=0.337, p=0.008), MITAX (r=0.357, p=0.004) and global disease assessment evaluated by a doctor (r=0.309, p=0.015). In patients with DM, positive correlations with MYOACT (r=0.499, p=0.009), MITAX (r=0.491, p=0.009), HAQ (r=0.470, p=0.014) and global disease assessment evaluated by a doctor (r=0.559, p=0.004) were found. No such associations were observed in PM or IMNM subsets.
Conclusion: We demonstrate increased local and systemic expression of clusterin in IIM patients compared to healthy individuals and its association with clinical disease activity, especially in patients with DM.
Acknowledgement: This study was supported by the project of MHCR for conceptual development of research organization 00023728, project NV16-33746A and project GAUK No. 534217.
To cite this abstract in AMA style:Lennerova T, Vernerova L, Klein M, Hruskova V, Andres Cerezo L, Sumova B, Tomcik M, Oreska S, Mann HF, Zamecnik J, Pavelka K, Vencovsky J, Senolt L. Clusterin Is Upregulated in Muscle Tissue and Serum in Idiopathic Inflammatory Myopathies and Is Associated with Clinical Disease Activity [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/clusterin-is-upregulated-in-muscle-tissue-and-serum-in-idiopathic-inflammatory-myopathies-and-is-associated-with-clinical-disease-activity/. Accessed January 19, 2020.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/clusterin-is-upregulated-in-muscle-tissue-and-serum-in-idiopathic-inflammatory-myopathies-and-is-associated-with-clinical-disease-activity/